

10/511818

DT05 Rec'd PCT/PTO 19 OCT 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Meir Strahilevitz

GROUP ART UNIT:

SERIAL NO.:

EXAMINER:

FILED:

DOCKET NO.: STRM 8432

FOR: METHODS AND DEVICES FOR TARGETING A SITE IN A MAMMAL AND  
FOR REMOVING SPECIES FROM A MAMMAL

**U.S. National Stage of PCT/US03/12602**

October 19, 2004

Mail Stop PCT  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

**SPECIFICATION**

Please substitute the following paragraph for the paragraph beginning at page 19, line 9:

Autoantibodies specific to the  $\beta$ 1 Adrenergic receptor have been implicated in the etiology and pathogenesis of Idiopathic Dilated Cardiac Myopathy (IDCM) (G Wallukat et al: New England J. Med. Vol 347, No 22, Nov 28, 2002) who found that specific removal of these antibodies by the specific synthetic antigen in extra corporeal adsorption (ECA) leads to significant improvement in cardiac performance (utilizing Affina Coraffin<sup>®</sup> column). Numerous other autoantibodies have also been found in IDCM (Muller et al: Circulation, 2000, Vol 101, pp 385-391.) Of particular interest is the association of ICM IDCM with autoantibodies specific to Oxidized LDL (I Schimke et al: J Am College of Cardiol, 2001, Vol. 38, No 1, pp 178-183) found that following ECA using a sheep anti-human-immunoglobulin antibody, as the adsorbent, the level of autoantibodies specific to oxidized LDL, correlated negatively with lipid peroxide levels (indicator of oxidative stress) as well as with left ventricular ejection fraction. ECA was associated with significant decrease in the level of autoantibodies to the  $\beta$ 1 adrenergic receptor.